The company secures the funding to scale FluoTB and prepare its regional launch.
HerelleX has closed its first investment round, a step that takes the company from MVP clinical validation to production at scale.
The funds go to three fronts: expanding reagent production capacity, advancing the regulatory path and growing the scientific team.
Accessible diagnosis stops being a promise when production keeps up.
Get involved
The potential market is ~200,000 tests a year in Argentina and over 30 million a year across high-incidence countries — a global TB-diagnostics market projected to grow from USD 2.28B in 2024 to USD 3.18B by 2030. If accessible diagnosis is your mission too, let's talk.
Simplified view
A respiratory sample is processed with standard lab methods, incubated with our reagents, then fixed for safe fluorescence reading — even up to 10 days later.
01.
Decontamination
Competing flora is cleared.
02.
Infect and express
Sample meets phage reagents.
03.
Fixation
Fixed — safe to handle and store.